addS

Friday, 26 February 2016

Complete 2015-16 Induced Pluripotent Stem Cell (iPSC) Industry Report

Recent months have seen the first iPSC clinical trial in humans, creation of the world’s largest iPSC biobank, major funding awards, a historic challenge to the “Yamanaka Patent”, a Supreme Court ruling affecting industry patent rights, announcement of an iPSC cellular therapy clinic scheduled to open in 2019, and much more. Furthermore, iPSC patent dominance continues to cluster in specific geographic regions, while clinical trial and scientific publication trends give clear indicators of what may happen in the industry in 2015 and beyond. Is it worth it to get informed about rapidly-evolving market conditions and identify key industry trends that will give you an advantage over your competition?

To Download Sample Report With TOC@ http://www.researchmoz.us/enquiry.php?type=S&repid=288620

REPORT APPLICATIONS
This global strategic report is produced for:
Management of Stem Cell Product Companies
Management of Stem Cell Therapy Companies
Stem Cell Industry Investors
It is designed to increase your efficiency and effectiveness in:
Commercializing iPSC products, technologies, and therapies
Making intelligent investment decisions
Launching high-demand products
Selling effectively to your client base
Increasing revenue
Taking market share from your competition

OVERVIEW

Stem cell research and experimentation have been in process for well over five decades, as stem cells have the unique ability to divide and replicate repeatedly. In addition, their “unspecialized” nature allows them to differentiate into a wide variety of specialized cell types. The possibilities arising from these characteristics have resulted in great commercial interest, with potential applications ranging from the use of stem cells in reversal and treatment of disease, to targeted cell therapy, tissue regeneration, pharmacological testing on cell-specific tissues, and more.
Traditionally, scientists have worked with both embryonic and adult stem cells for research tools, as well as for cellular therapy. While the appeal of embryonic cells has been their ability to differentiate into any type of cell, there has been significant ethical, moral, and spiritual controversy surrounding their use. Although some adult stem cells do have differentiation capacity, it is often limited in nature, which results in fewer options for use.

Thus, induced pluripotent stem cells represent a promising combination of adult and embryonic stem cell characteristics.

Discovery of Induced Pluripotent Stem Cells


Groundbreaking experimentation in 2006 led to the introduction of induced pluripotent stem cells (iPSCs). These are adult cells which are isolated and then transformed into embryonic-like stem cells through the manipulation of gene expression, as well as other methods. Research and experimentation using mouse cells by Shinya Yamanaka’s lab at Kyoto University in Japan was the first instance in which there was successful generation of iPSCs. In 2007, a series of follow-up experiments was done at Kyoto University in which human adult cells were transformed into iPSC cells. Nearly simultaneously, a research group led by James Thomson at the University of Wisconsin-Madison accomplished the same feat of deriving iPSC lines from human somatic cells.

Over the next few years, iPSC research advances accelerated exponentially. 2013 was the first time in which clinical research involving transplant of iPSCs into humans was initiated, led by Masayo Takahashi of the RIKEN Center for Developmental Biology in Kobe, Japan. Dr. Takahashi and her team are investigating the safety of iPSC-derived cell sheets in patients with wet-type age-related macular degeneration. While the trial was initiated in 2013 and production of iPSCs from patients began at that time, it was not until August of 2014 that the first patient was implanted with retinal tissue generated using iPSCs derived from her own skin cells. Also, Kyoto University Hospital in Kobe, Japan announced in February of 2015 that it will be opening an iPSC therapy center in 2019, for purposes of conducting clinical studies on iPSC therapies.
More ....

To Enquire Regarding This Report@ http://www.researchmoz.us/enquiry.php?type=E&repid=288620

About ResearchMoz

ResearchMoz is the world’s fastest growing collection of market research reports worldwide. Our database is composed of current market studies from over 100 featured publishers worldwide. Our market research databases integrate statistics with analysis from global, regional, country and company perspectives. ResearchMoz’s service portfolio also includes value-added services such as market research customization, competitive landscaping, and in-depth surveys, delivered by a team of experienced Research Coordinators.

Blog: http://dynamicmarketresearch.blogspot.com/

No comments:

Post a Comment